Kajungu Dan, Nambasa Victoria, Muhoozi Michael, Tusabe Joan, Kampmann Beate, Todd Jim
Makerere University Centre for Health and Population Research (MUCHAP), Makerere University, Kampala P.O. Box 7062, Uganda.
Department of Global Health, Stellenbosch University, Stellenbosch 7602, South Africa.
Vaccines (Basel). 2021 Nov 8;9(11):1293. doi: 10.3390/vaccines9111293.
Active vaccine pharmacovigilance complements the standard passive or spontaneous surveillance system, which suffers from low reporting rates. This study aimed at utilizing population-based structures to report and profile adverse events following immunization (AEFI) with the measles and rubella vaccine (MR), or MR in combination with the bivalent oral polio vaccine (bOPV 1&3) (MR & bOPV), during mass vaccination in Uganda. Caretakers of children at home (less than 5 years) and schoolgoing children were followed up on and encouraged to report any AEFIs on day one, 2-3 days, 10 days, and 14 days after vaccination at school by their teachers and at-home, community-based village health teams. Out of 9798 children followed up on, 382 (3.9%) reported at least one AEFI, and in total, 517 AEFIs were reported. For MR, high temperature (21%), general feeling of weakness (19.3%), and headache (13%) were the most reported AEFIs, though there were variations on the days when they were reported. For the combination dose of MR & bOPV, high temperature (44%), rash (17%), general feeling of weakness (13%), and diarrhoea (8%) were the most common adverse events following immunization reported by caretakers. All 382 children cleared the AEFIs within 2 days, with 343 (90%) children reporting mild or moderate AEFIs and only 39 (10%) reporting severe AEFIs. The reported AEFIs are known and are mentioned in the vaccine leaflets with similar severity classification. Rates of AEFIs differed with the number of days after receiving the immunization. Conclusion: Active surveillance for AEFIs provides additional important information to national vaccine regulatory bodies. It reassures the public that vaccines are safe and that their safety is being taken seriously in Uganda, which would improve vaccine acceptability and confidence in the health system. Piggybacking on existing structures such as village health team members (for children at home) and teachers (for schoolgoing children) facilitates reaching vaccine recipients and increases reporting rates. Therefore, studies using active reporting of AEFIs should be conducted at regular intervals to report the overall incidence of AEs and to monitor trends and changes.
主动疫苗药物警戒是对标准的被动或自发监测系统的补充,后者存在报告率低的问题。本研究旨在利用基于人群的结构,报告乌干达大规模疫苗接种期间麻疹风疹疫苗(MR)或MR与二价口服脊髓灰质炎疫苗(bOPV 1&3)联合接种(MR & bOPV)后的免疫接种不良事件(AEFI)并进行分析。对家中儿童(5岁以下)和学龄儿童的监护人进行随访,并鼓励他们在接种疫苗后的第1天、2 - 3天、10天和14天,由学校老师以及家中基于社区的乡村卫生团队报告任何AEFI。在随访的9798名儿童中,382名(3.9%)报告了至少一种AEFI,共报告了517起AEFI。对于MR疫苗,最常报告的AEFI是高温(21%)、全身乏力感(19.3%)和头痛(13%),不过报告这些症状的天数有所不同。对于MR与bOPV的联合剂量,监护人报告的免疫接种后最常见不良事件是高温(44%)、皮疹(17%)、全身乏力感(13%)和腹泻(8%)。所有382名儿童在2天内AEFI症状消失,其中343名(90%)儿童报告的是轻度或中度AEFI,只有39名(10%)报告的是重度AEFI。报告的AEFI是已知的,并且在疫苗说明书中有类似的严重程度分类。AEFI的发生率因接种疫苗后的天数而异。结论:对AEFI进行主动监测为国家疫苗监管机构提供了额外的重要信息。这让公众放心,疫苗是安全的,并且在乌干达其安全性正受到认真对待,这将提高疫苗的可接受性以及对卫生系统的信心。借助现有的结构,如乡村卫生团队成员(针对家中儿童)和教师(针对学龄儿童),便于接触到疫苗接种者并提高报告率。因此,应定期开展使用AEFI主动报告的研究,以报告不良事件的总体发生率,并监测趋势和变化。